About XO1
XO1 is a company based in Cambridge (United Kingdom) founded in 2012 was acquired by Janssen Pharmaceutica in March 2015.. XO1 has raised $11 million across 1 funding round from investors including Johnson & Johnson Innovative Medicine, University of Cambridge and LRM. XO1 operates in a competitive market with competitors including Portola Pharma, Alexion, argenx, MyoKardia and Cellino, among others.
- Headquarter Cambridge, United Kingdom
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xo1 Limited
- Date of Incorporation 28 Feb, 2013
- Jurisdiction HIGH WYCOMBE, BUCKINGHAMSHIRE
-
Annual Revenue
$1.29 K (USD)0as on Jan 31, 2021
-
Net Profit
$-126.25 K (USD)0as on Dec 30, 2017
-
EBITDA
-
Total Equity Funding
$11 M (USD)
in 1 rounds
-
Latest Funding Round
$11 M (USD), Series A
Jun 06, 2013
- Investors
-
Employee Count
Employee Count
-
Acquired by
Janssen Pharmaceutica
(Mar 19, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of XO1
XO1 has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Series A round of $11 million completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $11.0M
-
First Round
First Round
(06 Jun 2013)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2013 | Amount | Series A - XO1 | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in XO1
XO1 has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Johnson & Johnson Innovative Medicine, University of Cambridge and LRM. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
LRM is engaged in providing risk capital and smart money to businesses in Limburg.
|
Founded Year | Domain | Location | |
|
Multiple courses and degrees are offered across diversified academic streams.
|
Founded Year | Domain | Location | |
|
Diversified drugs are manufactured for various therapeutic areas.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by XO1
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - XO1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xo1 Comparisons
Competitors of XO1
XO1 operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, Alexion, argenx, MyoKardia and Cellino, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| domain | founded_year | HQ Location |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| domain | founded_year | HQ Location |
Specialized drugs are developed for genetic heart diseases.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about XO1
When was XO1 founded?
XO1 was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is XO1 located?
XO1 is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Is XO1 a funded company?
XO1 is a funded company, having raised a total of $11M across 1 funding round to date. The company's 1st funding round was a Series A of $11M, raised on Jun 06, 2013.
What is the annual revenue of XO1?
Annual revenue of XO1 is $1.29K as on Jan 31, 2021.
What does XO1 do?
XO1, a spin-out from the University of Cambridge was a virtual biopharmaceutical company developing anti-thrombin antibody to treat heart attacks and strokes. Its lead product Ichorcumab is a recombinant human antibody developed to mimic the activity of a human antibody that appears to produce an anticoagulated state without predisposition to bleeding. In March 2015, Janssen acquired XO1 for an undisclosed amount.
Who are the top competitors of XO1?
XO1's top competitors include argenx, Kodiak Sciences and Tenaya Therapeutics.
Who are XO1's investors?
XO1 has 3 investors. Key investors include Johnson & Johnson Innovative Medicine, University of Cambridge, and LRM.